|
First-line immunochemotherapy for follicular lymphoma in the GALLIUM study: Prognostic value of PET-CT status after long-term follow-up. |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
Speakers' Bureau - Roche; Takeda |
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celleron Therapeutics (Inst); Roche (Inst) |
|
|
|
Travel, Accommodations, Expenses - Roche |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
|
|
|
Consulting or Advisory Role - Roche |
|
|
|
|
|
Honoraria - Celgene; Janssen; Roche |
Consulting or Advisory Role - Celgene; Janssen; Roche |
Speakers' Bureau - Celgene; Janssen; Roche |
Research Funding - Bayer; Janssen; Roche |
Travel, Accommodations, Expenses - Celgene; Janssen; Roche |
|
|
No Relationships to Disclose |
|
|
Research Funding - Beigene (Inst); celgene (Inst); Janssen-Cilag (Inst); Pharmacyclics (Inst); Roche/Genentech (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Roche/Genentech |